This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total (154 received the drug-eluting balloon, and 155 received the everolimus-eluting stent). There were no differences in the characteristics of both groups. At one year the rate of cardiac death, myocardial infarction and target vessel revascularization was 10% for the everolimus-eluting stent and 18% for the drug-eluting balloon (p = 0.008). The need for revascularization of the target vessel was 4 versus 13%, respectively (p = 0.008).
Conclusion
The everolimus-eluting stent showed better angiographic and clinical outcomes than the drug-eluting balloon to treat patients with in-stent restenosis.
Fernando Alfonso
2014-09-15
Original title: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents.